KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances

West Pharmaceutical Services (WST) Shares Repurchased (2016 - 2026)

West Pharmaceutical Services has reported Shares Repurchased over the past 15 years, most recently at $297.6 million for Q1 2026.

Quarterly Shares Repurchased rose 122.92% to $297.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $298.1 million through Mar 2026, down 30.25% year-over-year, with the annual reading at $134.0 million for FY2025, 76.11% down from the prior year.
Shares Repurchased was $297.6 million for Q1 2026 at West Pharmaceutical Services, up from $500000.0 in the prior quarter.
Over five years, Shares Repurchased peaked at $297.6 million in Q1 2026 and troughed at -$100000.0 in Q4 2022.
The 5-year median for Shares Repurchased is $60.1 million (2023), against an average of $108.9 million.
Biggest five-year swings in Shares Repurchased: skyrocketed 177100.0% in 2023 and later plummeted 99.73% in 2025.
Tracing WST's Shares Repurchased over 5 years: stood at -$100000.0 in 2022, then skyrocketed by 177100.0% to $177.0 million in 2023, then plummeted by 69.27% to $54.4 million in 2024, then crashed by 99.08% to $500000.0 in 2025, then surged by 59420.0% to $297.6 million in 2026.
According to Business Quant data, Shares Repurchased over the past three periods came in at $297.6 million, $500000.0, and $133.5 million for Q1 2026, Q2 2025, and Q1 2025 respectively.